CR20200421A - Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el càncer - Google Patents

Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el càncer

Info

Publication number
CR20200421A
CR20200421A CR20200421A CR20200421A CR20200421A CR 20200421 A CR20200421 A CR 20200421A CR 20200421 A CR20200421 A CR 20200421A CR 20200421 A CR20200421 A CR 20200421A CR 20200421 A CR20200421 A CR 20200421A
Authority
CR
Costa Rica
Prior art keywords
phenyl
pyrimidine
cancer
related compounds
fluoro
Prior art date
Application number
CR20200421A
Other languages
English (en)
Spanish (es)
Inventor
Evan Styduhar
Qinda Ye
Alexander Sokolsky
Oleg Vechorkin
Jun Pan
Wenqing Yao
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of CR20200421A publication Critical patent/CR20200421A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CR20200421A 2018-02-20 2019-02-19 Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el càncer CR20200421A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862632702P 2018-02-20 2018-02-20
US201862672772P 2018-05-17 2018-05-17
US201862750371P 2018-10-25 2018-10-25
PCT/US2019/018608 WO2019164846A1 (en) 2018-02-20 2019-02-19 N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer

Publications (1)

Publication Number Publication Date
CR20200421A true CR20200421A (es) 2021-01-26

Family

ID=65635851

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200421A CR20200421A (es) 2018-02-20 2019-02-19 Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el càncer

Country Status (32)

Country Link
US (3) US10800761B2 (enExample)
EP (1) EP3755703B1 (enExample)
JP (1) JP7526673B2 (enExample)
KR (1) KR20200133747A (enExample)
CN (1) CN112292380B (enExample)
AU (1) AU2019223955B2 (enExample)
BR (1) BR112020016927A2 (enExample)
CA (1) CA3091517A1 (enExample)
CL (1) CL2020002146A1 (enExample)
CO (1) CO2020011530A2 (enExample)
CR (1) CR20200421A (enExample)
CY (1) CY1125401T1 (enExample)
DK (1) DK3755703T3 (enExample)
EC (1) ECSP20058964A (enExample)
ES (1) ES2922237T3 (enExample)
HR (1) HRP20220833T1 (enExample)
HU (1) HUE059624T2 (enExample)
IL (1) IL276779B2 (enExample)
LT (1) LT3755703T (enExample)
MD (1) MD3755703T2 (enExample)
MX (1) MX2020008656A (enExample)
PE (1) PE20210397A1 (enExample)
PH (1) PH12020551278A1 (enExample)
PL (1) PL3755703T3 (enExample)
PT (1) PT3755703T (enExample)
RS (1) RS63659B1 (enExample)
SG (1) SG11202007917VA (enExample)
SI (1) SI3755703T1 (enExample)
SM (1) SMT202200294T1 (enExample)
TW (1) TWI828653B (enExample)
UA (1) UA128286C2 (enExample)
WO (1) WO2019164846A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR109596A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos pirazolopiridina y sus usos
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
DK3755703T3 (da) 2018-02-20 2022-06-27 Incyte Corp N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
WO2020068729A1 (en) 2018-09-25 2020-04-02 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
AU2019401495B2 (en) 2018-12-20 2025-06-26 Amgen Inc. Heteroaryl amides useful as KIF18A inhibitors
AU2019404576B2 (en) * 2018-12-20 2025-07-17 Amgen Inc. Heteroaryl amides useful as KIF18A inhibitors
MA54550A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
BR112021016522A2 (pt) 2019-02-22 2021-10-26 Hanmi Pharm. Co., Ltd. Composição farmacêutica para o tratamento da leucemia mieloide aguda
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
EP3991733A4 (en) 2019-06-27 2023-07-05 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents
AU2020325115B2 (en) 2019-08-02 2026-03-12 Amgen Inc. Pyridine derivatives as KIF18A inhibitors
JP7699100B2 (ja) 2019-08-02 2025-06-26 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤
KR20220059480A (ko) * 2019-08-06 2022-05-10 인사이트 코포레이션 고체 형태의 hpk1 억제제
WO2021249913A1 (en) 2020-06-09 2021-12-16 Bayer Aktiengesellschaft 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
CN114181257B (zh) * 2020-09-14 2025-02-14 四川科伦博泰生物医药股份有限公司 吡啶类化合物，包含其的药物组合物，其制备方法及其用途
WO2022167627A1 (en) 2021-02-05 2022-08-11 Bayer Aktiengesellschaft Map4k1 inhibitors
WO2023001794A1 (en) 2021-07-20 2023-01-26 Astrazeneca Ab Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer
EP4377318A4 (en) * 2021-07-30 2025-06-04 BeiGene, Ltd. PYRROLO[2,3-B PYRAZINE-BASED BIFUNCTIONAL COMPOUNDS AS HPK1 DEGRADERS AND USE THEREOF
EP4463150A4 (en) * 2022-01-12 2026-03-18 Shenzhen Ionova Life Science Co Ltd HETEROARYL COMPOUNDS AS HPK1 INHIBITORS AND THEIR METHODS OF USE
CN117510400B (zh) * 2023-11-29 2026-02-06 山西永津集团有限公司 一种6-溴-2-氯-3-硝基吡啶的制备方法
WO2026039380A1 (en) * 2024-08-15 2026-02-19 Merck Sharp & Dohme Llc Alpha-synuclein binders and methods of use

Family Cites Families (250)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8800613D0 (sv) 1988-02-23 1988-02-23 Wallac Oy A novel spectrofluorometric method and compounds that are of value for the method
JPH03287584A (ja) 1990-04-05 1991-12-18 Banyu Pharmaceut Co Ltd 置換アリルアミン誘導体
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
DE19622270A1 (de) 1996-06-03 1997-12-04 Basf Ag Pyrimidin-4-carbonsäureamide
CA2288910C (en) 1997-04-25 2003-06-24 Pfizer Inc. Pyrazolopyrimidinones for sexual dysfunction
ES2203078T3 (es) 1998-04-20 2004-04-01 Pfizer Inc. Parazolopirimidinonas inhibidoras de gmpc pde5 para el tratamiento de la disfuncion sexual.
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823102D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
IN187433B (enExample) 1999-09-10 2002-04-27 Cipla Ltd
WO2001019827A1 (en) 1999-09-13 2001-03-22 Cipla Ltd. A novel process for the synthesis of sildenafil citrate
HK1053831A1 (zh) 1999-09-17 2003-11-07 Basf Aktiengesellschaft 作为治疗药物的激酶抑制剂
BR0014139B1 (pt) 1999-09-24 2011-09-20 derivado de diamida aromática ou um seu sal, composição agrìcola e hortìcola, e, método para utilizar uma composição agrìcola e hortìcola.
HK1049834A1 (zh) 1999-10-11 2003-05-30 辉瑞大药厂 用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4，3-d]嘧啶-7-酮类化合物
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
IL152925A (en) 1999-10-21 2010-04-15 Pfizer Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
KR100523718B1 (ko) 1999-12-22 2005-10-26 니혼노야쿠가부시키가이샤 방향족 디아미드 유도체, 농원예용 약제 및 이의 사용방법
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
US20020013327A1 (en) 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
WO2002016348A1 (en) 2000-08-09 2002-02-28 Astrazeneca Ab Antiangiogenic bicyclic derivatives
AU2001284417A1 (en) 2000-09-05 2002-03-22 Taisho Pharmaceutical Co. Ltd. Hair growth stimulants
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US7105532B2 (en) 2000-12-19 2006-09-12 Smithkline Beecham Corporation Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors
BR0115995A (pt) 2000-12-19 2004-01-13 Merck Patent Gmbh Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas ou derivados de prostaglandina
US6770645B2 (en) 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
US6784185B2 (en) 2001-03-16 2004-08-31 Pfizer Inc. Pharmaceutically active compounds
US7902179B2 (en) 2001-04-26 2011-03-08 Ajinomoto Co., Inc. Heterocyclic compounds
WO2002090347A1 (en) 2001-04-30 2002-11-14 Fujisawa Pharmaceutical Co., Ltd. Amide compounds
FR2825706B1 (fr) 2001-06-06 2003-12-12 Pf Medicament Nouveaux derives de benzothienyle ou d'indole, leur preparation et leur utilisation comme inhibiteurs de proteines prenyl transferase
KR20040053210A (ko) 2001-11-02 2004-06-23 화이자 프로덕츠 인크. Ｐｄｅ9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료
TW200303201A (en) 2001-12-10 2003-09-01 Bristol Myers Squibb Co Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
US7166293B2 (en) 2002-03-29 2007-01-23 Carlsbad Technology, Inc. Angiogenesis inhibitors
US20050119278A1 (en) 2002-05-16 2005-06-02 Che-Ming Teng Anti-angiogenesis methods
CN1656079A (zh) 2002-05-31 2005-08-17 卫材株式会社 吡唑化合物和含有该化合物的药物组合物
WO2004074286A1 (en) 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
US7531558B2 (en) 2003-02-14 2009-05-12 Glaxo Group Limited Carboxamide derivatives
EP1613747A1 (en) 2003-03-31 2006-01-11 Pfizer Products Inc. Crystal structure of 3 ,5 -cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof
KR100824193B1 (ko) 2003-04-29 2008-04-21 화이자 인코포레이티드 고혈압 치료에 유용한5,7-디아미노피라졸로[4,3-ｄ]피리미딘
US20050004133A1 (en) 2003-06-05 2005-01-06 Makings Lewis R. Modulators of VR1 receptor
JP2007505950A (ja) 2003-06-10 2007-03-15 フルクラム・ファーマシューティカルズ・インコーポレーテッド β−ラクタマーゼ阻害剤およびその使用方法
ZA200305330B (en) 2003-07-10 2004-05-26 Jb Chemicals & Pharmaceuticals An improved process for the preparation of 5-[2-ethoxy-5-(4-methylpiperazin-1-ylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazole[4,3-D]P yrimidin-7-one.
EP1648448A4 (en) 2003-07-29 2009-04-01 Smithkline Beecham Corp CHEMICAL COMPOUNDS
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
KR101190912B1 (ko) 2003-11-19 2012-10-12 어레이 바이오파마 인크. Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
US20050137398A1 (en) 2003-12-22 2005-06-23 Jianguo Ji 3-Quinuclidinyl heteroatom bridged biaryl derivatives
US7241773B2 (en) 2003-12-22 2007-07-10 Abbott Laboratories 3-quinuclidinyl heteroatom bridged biaryl derivatives
GB0402137D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
DE102004005172A1 (de) 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
CN1926139A (zh) 2004-02-27 2007-03-07 霍夫曼-拉罗奇有限公司 稠合吡唑衍生物
KR100844864B1 (ko) 2004-02-27 2008-07-09 에프. 호프만-라 로슈 아게 헤테로아릴-융합 피라졸로 유도체
JP2007526324A (ja) 2004-03-02 2007-09-13 スミスクライン・ビーチャム・コーポレイション Ａｋｔ活性のある阻害剤
AR050188A1 (es) 2004-08-03 2006-10-04 Uriach Y Compania S A J Compuestos heterociclicos condensados utiles en terapia como inhibidores de quinasas p38 y composiciones farmaceuticas que los contienen
WO2006028958A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
WO2006038001A1 (en) 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
US7846915B2 (en) 2004-10-20 2010-12-07 Resverlogix Corporation Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
JP2008518926A (ja) 2004-10-28 2008-06-05 ジ インスティチューツ フォー ファーマシューティカル ディスカバリー、エルエルシー 置換フェニルアルカン酸
JP2008519850A (ja) 2004-11-10 2008-06-12 シンタ ファーマシューティカルズ コーポレーション Ｉｌ−１２調節化合物
WO2006053109A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
JP2008519843A (ja) 2004-11-10 2008-06-12 シージーアイ ファーマスーティカル インコーポレーテッド 特定のイミダゾ［１，２−ａ］ビラジン−８−イラミンズ、その生成方法及びそれに関する使用方法
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
CN100516049C (zh) 2004-11-16 2009-07-22 永信药品工业股份有限公司 抗血管生成药n2-(取代的芳基甲基)-3-(取代的苯基)吲唑的合成
RU2007130077A (ru) 2005-01-07 2009-02-20 Эмори Юниверсити (Us) Антагонисты cxcr4 и их применение для лечения вич-инфекции
AU2006230364B2 (en) 2005-03-31 2012-09-13 Janssen Pharmaceutica N.V. Bicyclic pyrazole compounds as antibacterial agents
WO2006128172A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating b cell regulated autoimmune disorders
US20100216798A1 (en) 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
US7345178B2 (en) 2005-08-04 2008-03-18 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
GB0516703D0 (en) 2005-08-15 2005-09-21 Syngenta Participations Ag Novel insecticides
JP2007055940A (ja) 2005-08-24 2007-03-08 Astellas Pharma Inc ピラゾロピリミジン誘導体
EP1919913A2 (en) 2005-08-25 2008-05-14 F.Hoffmann-La Roche Ag P38 map kinase inhibitors and methods for using the same
CN101243051A (zh) 2005-08-25 2008-08-13 霍夫曼-拉罗奇有限公司 p38 MAP激酶抑制剂及使用它的方法
JP2009506007A (ja) 2005-08-25 2009-02-12 エフ．ホフマン−ラ ロシュ アーゲー ｐ３８ＭＡＰキナーゼ阻害剤及びその使用方法
US7915410B2 (en) 2005-09-09 2011-03-29 Bristol-Myers Squibb Company Acyclic IKur inhibitors
WO2007041511A2 (en) 2005-09-30 2007-04-12 New York University Hematopoietic progenitor kinase 1 for modulation of an immune response
EP1940296A2 (en) 2005-10-25 2008-07-09 SmithKline Beecham Corporation Chemical compounds
EP1948604A1 (en) 2005-11-03 2008-07-30 Ilypsa, Inc. Indole compounds having c4-acidic substituents and use thereof as phospholipase-a2 inhibitors
BRPI0619208A2 (pt) 2005-11-30 2011-09-20 Astellas Pharma Inc derivado de 2-aminobenzamida c07d 307/14 c07d 307/22 c07d 309/14 c07d 319/12 c07d 401/12 c07d 405/12 c07d 413/12 c07d 417/12
GB0525143D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
KR20080083188A (ko) 2006-01-11 2008-09-16 아스트라제네카 아베 모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도
EP1984354B1 (en) 2006-02-16 2009-08-05 Syngeta Participations AG Pesticides containing a bicyclic bisamide structure
AU2007230911A1 (en) 2006-03-23 2007-10-04 Synta Pharmaceuticals Corp. Benzimidazolyl-pyridine compounds for inflammation and immune-related uses
PL1999132T3 (pl) 2006-03-30 2012-12-31 Irm Llc Azolopirymidyny jako inhibitory aktywności Receptora Kannabinoidowego typu 1
NZ573735A (en) 2006-05-19 2011-10-28 Abbott Lab Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
GB0614691D0 (en) 2006-07-24 2006-08-30 Syngenta Participations Ag Insecticidal compounds
WO2008045627A2 (en) 2006-10-06 2008-04-17 Irm Llc Protein kinase inhibitors and methods for using thereof
CN101528747A (zh) 2006-10-20 2009-09-09 康塞特医药品有限公司 3-(二氢-1H-吡唑并[4,3-d]嘧啶-5-基)-4-丙氧基苯磺酰胺衍生物和使用方法
US20080200458A1 (en) 2007-01-18 2008-08-21 Joseph Barbosa Methods and compositions for the treatment of body composition disorders
WO2008089307A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
US20140249135A1 (en) * 2007-03-01 2014-09-04 Novartis Ag Pim kinase inhibitors and methods of their use
CN101679266B (zh) 2007-03-01 2015-05-06 诺华股份有限公司 Pim激酶抑制剂及其应用方法
EP2002835A1 (en) 2007-06-04 2008-12-17 GenKyo Tex Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
TW200916472A (en) * 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
BRPI0814441A2 (pt) 2007-07-19 2015-07-14 Schering Corp Compostos de amida heterocíclica como inibidores de proteína cinase
MY146643A (en) 2007-07-30 2012-09-14 Dae Woong Pharma Novel benzoimidazole derivatives and pharmaceutical composition comprising the same
US8399448B2 (en) 2007-08-08 2013-03-19 Merck Serono Sa 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis
GB0716414D0 (en) 2007-08-22 2007-10-03 Syngenta Participations Ag Novel insecticides
WO2009032651A1 (en) 2007-08-31 2009-03-12 Smithkline Beecham Corporation Inhibitors of akt activity
US8314131B2 (en) 2007-09-21 2012-11-20 Amgen Inc. Triazole fused heteroaryl compounds and methods of use thereof
EP2215066A1 (en) 2007-11-01 2010-08-11 Sirtris Pharmaceuticals, Inc. Amide derivatives as sirtuin modulators
KR100963644B1 (ko) 2007-11-23 2010-06-15 한국과학기술연구원 피라졸로피리미딘온 유도체 및 그의 제조방법
UA106037C2 (uk) 2008-02-04 2014-07-25 Мерк'Юрі Терап'Ютікс, Інк. Модулятори ampk (амф-активованої протеїнкінази)
WO2009139834A1 (en) 2008-05-13 2009-11-19 Poniard Pharmaceuticals, Inc. Bioactive compounds for treatment of cancer and neurodegenerative diseases
EA201001847A1 (ru) 2008-06-11 2011-08-30 Айрм Ллк Соединения и композиции, применяемые для лечения малярии
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
US20110294853A1 (en) 2008-09-12 2011-12-01 Benjamin Pelcman Bis Aromatic Compounds for Use in the Treatment of Inflammation
EP2166008A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2165707A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166010A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
WO2010046780A2 (en) 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
KR101685718B1 (ko) 2008-12-19 2016-12-12 제넨테크, 인크. 헤테로시클릭 화합물 및 사용 방법
WO2010104306A2 (ko) 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
JP2012520887A (ja) 2009-03-18 2012-09-10 シェーリング コーポレイション ジアシルグリセロールアシルトランスフェラーゼの阻害剤としての二環式化合物
EP2411328B1 (en) 2009-03-26 2019-07-24 Northeastern University Carbon nanostructures from pyrolysis of organic materials
WO2010118367A2 (en) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
WO2011019780A1 (en) 2009-08-11 2011-02-17 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
EP2477498A4 (en) 2009-09-14 2013-02-27 Merck Sharp & Dohme INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE
WO2012109263A1 (en) 2011-02-07 2012-08-16 The Washington University Mannoside compounds and methods of use thereof
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
ES2360333B1 (es) 2009-10-29 2012-05-04 Consejo Superior De Investigaciones Cientificas (Csic) (70%) Derivados de bis (aralquil) amino y sistemas (hetero) aromaticos de seis miembros y su uso en el tratamiento de patologias neurodegenerativas, incluida la enfermedad de alzheimer
JP2013032290A (ja) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
WO2011078143A1 (ja) 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
WO2011079236A1 (en) 2009-12-22 2011-06-30 The Ohio State University Research Foundation Compositions and methods for cancer detection and treatment
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
US20130109758A1 (en) 2010-01-06 2013-05-02 The University Of British Columbia Bisphenol derivative therapeutics and methods for their use
DE102010009903A1 (de) 2010-03-02 2011-09-08 Merck Patent Gmbh Verbindungen für elektronische Vorrichtungen
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
JP6112486B2 (ja) 2010-04-27 2017-04-12 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
KR20110123657A (ko) 2010-05-07 2011-11-15 에스케이케미칼주식회사 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
GB201008134D0 (en) 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
JP2011246389A (ja) 2010-05-26 2011-12-08 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有する縮環ピラゾール誘導体
JP2013528169A (ja) 2010-05-27 2013-07-08 バイエル・クロップサイエンス・アーゲー 殺菌剤としてのピリジニルカルボン酸誘導体
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
JP5993846B2 (ja) 2010-06-15 2016-09-14 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ アントラニル酸誘導体
EP2582666B1 (en) 2010-06-16 2014-08-13 Purdue Pharma L.P. Aryl substituted indoles and their use as blockers of sodium channels
JP5926727B2 (ja) 2010-07-28 2016-05-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾ［１，２−ｂ］ピリダジン
US10005750B2 (en) 2010-10-06 2018-06-26 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
JP2014500277A (ja) 2010-12-09 2014-01-09 アムジエン・インコーポレーテツド Ｐｉｍ阻害剤としての二環式化合物
CN103261188A (zh) 2010-12-17 2013-08-21 先正达参股股份有限公司 杀虫化合物
CN103402996B (zh) 2011-01-04 2015-02-11 诺瓦提斯公司 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物
KR20140020972A (ko) 2011-03-28 2014-02-19 에프. 호프만-라 로슈 아게 티아졸로피리미딘 화합물
PH12013501829A1 (en) 2011-04-12 2015-10-23 Chong Kun Dang Pharmaceutical Corp Cycloalkenyl aryl derivatives for cetp inhibitor
AU2012244550C1 (en) 2011-04-21 2017-06-22 Origenis Gmbh Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
WO2012151567A1 (en) 2011-05-05 2012-11-08 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for preventing and treating influenza
WO2012158810A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Tyrosine kinase inhibitors
CA2836203A1 (en) 2011-05-17 2012-11-22 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
UY34104A (es) 2011-05-31 2013-01-03 Syngenta Participations Ag ?compuestos derivados benzamídicos heterocíclicos, procesos e intermedios para su preparación, composiciones y métodos para su uso?.
CA2837630A1 (en) 2011-06-01 2012-12-06 Knut Eis Substituted aminoimidazopyridazines
EP2723748B1 (en) 2011-06-22 2016-10-12 Bayer Intellectual Property GmbH Heterocyclyl aminoimidazopyridazines
EP2729146B1 (en) 2011-07-08 2017-03-08 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for treatment of liver cancer
EP2543372A1 (en) 2011-07-08 2013-01-09 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for the treatment of liver cancer
US9394293B2 (en) 2011-08-10 2016-07-19 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
RU2014105624A (ru) 2011-08-12 2015-09-20 Ф. Хоффманн-Ля Рош Аг Соединения индазола, способ их применения и фармацевтическая композиция
US9260425B2 (en) 2011-08-12 2016-02-16 Genetech, Inc. Pyrazolo[3,4-c]pyridine compounds and methods of use
WO2013042137A1 (en) 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
US9320737B2 (en) 2011-09-23 2016-04-26 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
CN102516263B (zh) 2011-10-25 2015-04-08 南方医科大学 一种螺三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
CN102503959B (zh) 2011-10-25 2015-04-08 南方医科大学 一种稠三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
EP2773645A1 (en) 2011-11-01 2014-09-10 F.Hoffmann-La Roche Ag Imidazopyridazine compounds
MX359989B (es) 2012-02-17 2018-10-18 Siga Tech Inc Fármacos antivirales para el tratamiento de la infección por arenavirus.
TW201348231A (zh) 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
CN104169260A (zh) 2012-03-09 2014-11-26 卡尔那生物科学株式会社 新三嗪衍生物
WO2013146942A1 (ja) 2012-03-28 2013-10-03 出光興産株式会社 新規化合物、有機エレクトロルミネッセンス素子用材料および有機エレクトロルミネッセンス素子
ES2571479T3 (es) 2012-04-20 2016-05-25 Gilead Sciences Inc Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH
WO2014003405A1 (ko) 2012-06-26 2014-01-03 주식회사 제이앤드제이 캐미칼 신규한 화합물 및 이를 포함하는 발광소자
US20150191462A1 (en) 2012-06-28 2015-07-09 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
KR101936851B1 (ko) 2012-07-16 2019-01-11 한국과학기술연구원 단백질 키나아제 저해제인 신규 피라졸로피리딘 유도체 또는 인다졸 유도체
WO2014024125A1 (en) 2012-08-08 2014-02-13 Celon Pharma S.A. Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors
JPWO2014030716A1 (ja) 2012-08-23 2016-08-08 田辺三菱製薬株式会社 ピラゾロピリミジン化合物
WO2014047616A1 (en) 2012-09-24 2014-03-27 Arizona Board Of Regents For And On Behalf Of Arizona State University Metal compounds, methods, and uses thereof
JP6457942B2 (ja) 2012-10-05 2019-01-23 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ−８阻害剤
US9604930B2 (en) 2012-12-21 2017-03-28 Epizyme, Inc. Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof
KR102137472B1 (ko) 2013-02-08 2020-07-27 삼성디스플레이 주식회사 유기 발광 소자
US10273243B2 (en) 2013-03-14 2019-04-30 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
HUE033542T2 (en) 2013-04-03 2017-12-28 Janssen Sciences Ireland Uc Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B
US8853278B1 (en) 2013-05-22 2014-10-07 Curza Global, Llc Compositions comprising a biocidal polyamine
US9673409B2 (en) 2013-06-10 2017-06-06 Arizona Board Of Regents On Behalf Of Arizona State University Phosphorescent tetradentate metal complexes having modified emission spectra
WO2015026683A1 (en) 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
WO2015037965A1 (en) 2013-09-16 2015-03-19 Rohm And Haas Electronic Materials Korea Ltd. Novel organic electroluminescent compounds and organic electroluminescent device comprising the same
WO2015058163A2 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10329270B2 (en) 2013-10-21 2019-06-25 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
WO2015089327A1 (en) 2013-12-11 2015-06-18 Biogen Idec Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
USRE50030E1 (en) 2013-12-13 2024-07-02 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
EP3083589B1 (en) 2013-12-20 2019-12-18 Sunshine Lake Pharma Co., Ltd. Substituted piperazine compounds and methods of use thereof
HK1231480A1 (zh) 2014-01-10 2017-12-22 Aurigene Discovery Technologies Limited 作为irak4抑制剂的吲唑化合物
KR102349550B1 (ko) 2014-02-05 2022-01-11 메르크 파텐트 게엠베하 금속 착물
EP3110419A4 (en) 2014-02-25 2017-07-26 Achillion Pharmaceuticals, Inc. Alkyne compounds for treatment of complement mediated disorders
US9871208B2 (en) 2014-02-26 2018-01-16 Samsung Display Co., Ltd. Condensed cyclic compound and organic light-emitting device including the same
WO2015164956A1 (en) 2014-04-29 2015-11-05 The University Of British Columbia Benzisothiazole derivative compounds as therapeutics and methods for their use
US20150328188A1 (en) 2014-05-19 2015-11-19 Everardus O. Orlemans Combination Therapies for the Treatment of Proliferative Disorders
WO2015192939A1 (de) 2014-06-18 2015-12-23 Merck Patent Gmbh Materialien für organische elektrolumineszenzvorrichtungen
CA2952188A1 (en) 2014-06-20 2015-12-23 Aurigene Discovery Technologies Limited Substituted indazole compounds as irak4 inhibitors
US11279714B2 (en) 2014-06-20 2022-03-22 Institut Pasteur Korea Anti-infective compounds
WO2015200680A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US20170247366A1 (en) 2014-06-25 2017-08-31 Vanderbilt University Substituted 4-alkoxypicolinamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
KR20160007967A (ko) 2014-07-10 2016-01-21 삼성디스플레이 주식회사 유기 발광 소자
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040188A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016041618A1 (en) 2014-09-15 2016-03-24 Merck Patent Gmbh Substituted indazoles and related heterocycles
CN107001362A (zh) 2014-10-06 2017-08-01 默克专利有限公司 用作btk抑制剂的杂芳基化合物及其用途
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
EP3227337A1 (en) 2014-12-05 2017-10-11 F. Hoffmann-La Roche AG Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
KR102554987B1 (ko) 2015-02-03 2023-07-12 메르크 파텐트 게엠베하 금속 착물
US10766860B2 (en) 2015-03-06 2020-09-08 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
CN107635984B (zh) 2015-03-11 2021-04-13 Fmc公司 杂环取代的二环唑杀有害生物剂
WO2016161571A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. Indazole and azaindazole btk inhibitors
WO2016174183A1 (en) 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
RS61919B1 (sr) * 2015-06-25 2021-06-30 Univ Health Network Inhibitori hpk1 i postupci za njihovo korišćenje
EP3322409A4 (en) 2015-07-15 2019-07-24 Aurigene Discovery Technologies Limited SUBSTITUTED AZA COMPOUNDS AS IRAQ-4 INHIBITORS
CA2992406A1 (en) 2015-07-15 2017-01-19 Aurigene Discovery Technologies Limited Indazole and azaindazole compounds as irak-4 inhibitors
EP3331530A4 (en) 2015-08-03 2018-12-19 Raze Therapeutics Inc. Mthfd2 inhibitors and uses thereof
US10195185B2 (en) 2015-08-03 2019-02-05 Samumed, Llc 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
CA2995094A1 (en) 2015-08-07 2017-02-16 Calcimedica, Inc. Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury
WO2017045955A1 (en) 2015-09-14 2017-03-23 Basf Se Heterobicyclic compounds
US10975071B2 (en) 2015-09-28 2021-04-13 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017108744A1 (de) 2015-12-22 2017-06-29 Bayer Pharma Aktiengesellschaft Neue substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2017120429A1 (en) 2016-01-07 2017-07-13 CS Pharmasciences, Inc. Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
WO2018015255A1 (en) 2016-07-19 2018-01-25 CUMMINGS, Arthur Bernard Artificial accommodating lens complex
CN110818690B (zh) 2016-07-26 2021-08-10 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
AR109596A1 (es) * 2016-09-09 2018-12-26 Incyte Corp Compuestos pirazolopiridina y sus usos
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
DK3755703T3 (da) 2018-02-20 2022-06-27 Incyte Corp N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
CN118286225A (zh) 2018-04-26 2024-07-05 辉瑞公司 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物
PE20210473A1 (es) 2018-05-04 2021-03-08 Novo Nordisk As Derivados de gip y usos de estos
SG11202010679SA (en) 2018-05-17 2020-11-27 Bayer Ag Substituted dihydropyrazolo pyrazine carboxamide derivatives
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
KR20220059480A (ko) 2019-08-06 2022-05-10 인사이트 코포레이션 고체 형태의 hpk1 억제제

Also Published As

Publication number Publication date
WO2019164846A1 (en) 2019-08-29
IL276779B2 (en) 2024-04-01
KR20200133747A (ko) 2020-11-30
SMT202200294T1 (it) 2022-11-18
US10800761B2 (en) 2020-10-13
EP3755703A1 (en) 2020-12-30
CA3091517A1 (en) 2019-08-29
PT3755703T (pt) 2022-08-16
CY1125401T1 (el) 2025-05-09
US20210094934A1 (en) 2021-04-01
PE20210397A1 (es) 2021-03-02
IL276779B1 (en) 2023-12-01
EP3755703B1 (en) 2022-05-04
US20190382380A1 (en) 2019-12-19
MX2020008656A (es) 2020-12-09
PH12020551278A1 (en) 2021-07-05
AU2019223955B2 (en) 2024-06-13
AU2019223955A1 (en) 2020-10-08
ES2922237T3 (es) 2022-09-12
UA128286C2 (uk) 2024-05-29
IL276779A (en) 2020-10-29
CN112292380B (zh) 2024-04-05
SG11202007917VA (en) 2020-09-29
TWI828653B (zh) 2024-01-11
HRP20220833T1 (hr) 2022-10-28
US11731958B2 (en) 2023-08-22
LT3755703T (lt) 2022-10-10
JP7526673B2 (ja) 2024-08-01
ECSP20058964A (es) 2020-12-31
SI3755703T1 (sl) 2022-11-30
CO2020011530A2 (es) 2020-12-10
TW201934548A (zh) 2019-09-01
JP2021515033A (ja) 2021-06-17
HUE059624T2 (hu) 2022-11-28
US12466815B2 (en) 2025-11-11
DK3755703T3 (da) 2022-06-27
CN112292380A (zh) 2021-01-29
CL2020002146A1 (es) 2021-01-29
RS63659B1 (sr) 2022-11-30
BR112020016927A2 (pt) 2020-12-15
MD3755703T2 (ro) 2022-10-31
US20240150326A1 (en) 2024-05-09
PL3755703T3 (pl) 2022-11-07

Similar Documents

Publication Publication Date Title
PH12020551278A1 (en) N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer
ZA202205900B (en) 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
ZA202110422B (en) Heterocyclic compounds, preparation methods and uses thereof
MX2021004624A (es) Derivados de 2-(2-acriloil-2,6-diazaspiro[3.4]octan-6-il)-6-(1h-in dazol-4-il)-benzonitrilo y compuestos relacionados como inhibidores de la proteina kras mutante g12c para inhibir metastasis de tumor.
MX2023004802A (es) Compuestos espiro heterocíclicos y métodos de uso.
PH12020551464A1 (en) Cd73 inhibitors
ZA202101788B (en) Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors
NZ777370A (en) Bicyclic derivatives
MX2023006606A (es) Derivados biciclicos.
MX2021007540A (es) Derivados biciclicos.
MX2020009887A (es) Derivados de aminopiridina como inhibidores de ctps1.
MX2009012709A (es) Derivados de arileter-piridazinona.
NZ603456A (en) 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer
TW200611907A (en) Fused heterocyclic compound
PH12016501440A1 (en) Novel heterocyclic compounds
PE20160115A1 (es) Compuestos derivados de imidazol como inhibidores de protein quinasa
EA032953B1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
UA116768C2 (uk) Дизаміщені бензотієнілпіролотриазини та їх застосування як інгібіторів кінази рфрф
NZ707432A (en) Pyrazolopyrimidine compounds
ATE522509T1 (de) Pyrimidylcyclopentane als inhibitoren der akt- proteinkinase
GEAP201914545A (en) Solid state forms of fused heteroaromatic pyrrolidinones
MX2018008362A (es) Derivados de quinolin-2-ona.
ZA202304734B (en) Alpha protein kinase 1 inhibitors and methods of use
TW200942543A (en) Pyrrolopyrazine kinase inhibitors
MX2023010910A (es) Nuevos inhibidores macrociclicos de la quinasa de lrrk2.